Disclosure of interest: Laurine Bedoucha : nothing to disclose Claire Gobron : nothing to disclose Fabrice Vallee : nothing to disclose Etienne Gayat : nothing to disclose Peggy Reiner : nothing to disclose Candice Sabben : nothing to disclose Michael Obadia : nothing to disclose Perrine Boursin : nothing to disclose Estelle Dubus : nothing to disclose Eric Jouvent : nothing to disclose Mikael Mazighi : nothing to disclose Lucas Di Meglio : nothing to disclose Poster Session I - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.01 - ACUTE MANAGEMENT - Neither thrombolysis nor thrombectomy P037 - ESOC25-504 CLINICAL AND ORGANISATIONAL PRACTICES IN THE ACUTE PHASE OF ISCHAEMIC STROKE IN QUEBEC BY SEX AND AGE: RESULTS OF A DESCRIPTIVE STUDY Amlie Blanger 1 , Julie Houle 1 , Line Beaudet 2 1 Universit du Qubec Trois-Rivires, Trois-Rivires, Canada, 2 Centre de recherche du Centre hospitalier de l'Universit de Montral (CRCHUM), Montral, Canada Background and Aims: The quality of interdisciplinary care during the acute phase of ischaemic stroke remains underexplored in Canada, particularly in Quebec
We do ask that before booking, you read the information on this page, and if you suspect you have low B12 but its unconfirmed, contact your GP for investigations
The peptide's biological activity in research models depends on its 1:1 chelation of a copper(II) ion
Volume of Distribution (V d ) Volume of distribution ( V d ) relates amount of drug in body to plasma concentration V d = (amount of drug in the body) / (plasma drug concentration) V d is changed in disease states that decrease plasma proteins a decrease in plasma proteins decreases binding of drug to plasma proteins e.g., liver disease e.g., kidney disease V d increased in disease states that increase total body water ascites, pulmonary edema, heart failure can lower plasma concentration of water soluble drugs V d predicts drug distribution in body low V d drugs medium V d drugs high V d drugs Clearance (CL) CL = (rate of elimination of drug) / (plasma drug concentration) = V d * K e K e = elimination constant CL relates the rate of elimination to the plasma concentration Half-Life (t 1/2 ) t 1/2 = (0.7 * V d )/CL half-life is time required for amount of drug to fall to 50% of an earlier measurement during elimination or during constant infusion a drug infused at a constant rate reaches about 94% of steady state after 4 half lives for drugs eliminated by first-order kinetics, half-life is constant regardless of concentration Bioavailability (F) bioavailability is the fraction of administered dose that reaches systemic circulation bioavailability is defined as unity, or 100%, in case of IV administration bioavailability of drug administered by other routes is generally reduced by incomplete absorption, first-pass metabolism, and any distribution into other tissues that occurs before the drug enters systemic circulation e.g., orally, F = percent that is absorbed and survives first-pass metabolism in liver Calculation of bioavailabillity (F) = 100% * (AUC-oral * Dose-IV) / (AUC-IV * Dose-oral), where AUC is the area under the curve of a pharmacokinetic plasma concentration versus time plot delayed release formulations will have slower rise and lower peak compared with rapid release formulations
